BLOOD CENTERS OF AMERICA, INC.

BLOOD CENTERS OF AMERICA, INC. specializes in the collection, processing, and manufacturing of convalescent plasma and serum products for therapeutic use in public health emergencies. Their core capabilities center on donor recruitment, apheresis-based plasma harvesting, pathogen reduction, viral inactivation, and cold-chain logistics for biological therapeutics. The organization demonstrates deep expertise in Good Manufacturing Practices (GMP) for human-derived biologics, with a focus on ensuring product safety, potency, and regulatory compliance under FDA oversight. Their ability to rapidly scale plasma collection and processing operations during public health crises represents a critical differentiator, particularly in the context of pandemic response. Technical proficiency includes serological testing, plasma fractionation, and the formulation of antibody-rich therapeutics for emergency use authorization pathways. The contractor maintains a consistent relationship with the Department of Health and Human Services, primarily supporting BARDA initiatives focused on pandemic preparedness and medical countermeasure development. Their work involves delivering investigational biological products under emergency use protocols, indicating a trusted partnership in biodefense and public health response programs. Their primary industry focus is medicinal and botanical manufacturing, specifically the production of human-derived plasma-based therapeutics. This places them at the intersection of transfusion medicine, immunotherapy, and emergency biomanufacturing, positioning them as a niche provider of life-saving biological products for federal health security programs. As a 2L entity based in West Warwick, Rhode Island, BLOOD CENTERS OF AMERICA, INC. operates as a specialized nonprofit blood services organization with a mission-driven focus on public health. While no formal government certifications are listed, their contract history confirms adherence to federal biologics manufacturing standards and emergency response protocols. Their geographic footprint supports regional donor networks critical to national biologics supply chains.